A randomized, phase II, multicenter, double-blind, placebo-controlled study evaluating the efficacy and safety of Onartuzumab (Met MAb) in combination with Paclitaxel + Cisplatin or Carboplatin as first-line treatment
|Effective start/end date||9/15/12 → 9/30/16|
- GENENTECH, INC.
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.